Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Launched by AMY ARNOLD · Dec 14, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a hormone called angiotensin-(1-7) to see how it affects energy balance in people who are obese. The researchers want to find out if this hormone can help increase the amount of energy your body uses while at rest and if it plays a role in producing heat in fat tissue. The goal is to better understand how this hormone could be used to help manage obesity.

To participate in the trial, you need to be between 18 and 60 years old, have a body mass index (BMI) between 30 and 40 (which classifies you as obese), and be able to give consent. Unfortunately, certain groups of people, such as those with specific health conditions or who have recently lost or gained significant weight, cannot participate. If you join, you can expect to undergo tests and evaluations to measure how angiotensin-(1-7) affects your energy expenditure, which could lead to new insights into obesity treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women of all races
• • Capable of giving informed consent
• • Age 18-60 years
• • Body mass index (BMI) between 30-40 kg/m2
• • Satisfactory history and physical exam
• Exclusion Criteria:
• • Age ≤ 17 or ≥ 61 years
• • Pregnant, nursing, or postmenopausal women
• • Decisional impairment
• • Prisoners
• • Alcohol or drug abuse
• • Current smokers
• • Highly trained athletes
• • Claustrophobia
• • Subjects with \>5% weight change in the past 3 months
• • Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
• • History of serious cardiovascular disease other than hypertension (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack).
• • History or presence of immunological or hematological disorders
• • Impaired hepatic function (aspartate aminotransferase or alanine aminotransferase levels \>2 times upper limit of normal range)
• • Impaired renal function (serum creatinine \>2.0 mg/dl)
• • Anemia
• • Treatment with anticoagulants (e.g. warfarin)
• • Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
• • Treatment with medications influencing energy expenditure (e.g. psychostimulants)
• • Treatment with any investigational drug in the 1-month preceding the study
• • Inability to give, or withdraw, informed consent